Foscarnet Sodium

膦甲酸钠

Report date: 2023/04/25 16:17:20
NME

Base Information

Drug NameFoscarnet Sodium
Drug Alias Namefoscarnet sodique膦甲酸三钠膦甲酸钠六水合物foscarnet de sodio羟基膦酸三钠 +[14] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionVirus DNA polymerase inhibitors
TargetsVirus DNA polymerase
Therapy Area/IndicationsGastrointestinal DiseasesHerpes SimplexHerpesviridae Infections +[6] 
Global Approved IndicationsHerpes SimplexHerpesviridae InfectionsCytomegalovirus Retinitis
Approved Indications in ChinaHerpesviridae InfectionsCytomegalovirus Retinitis
Original Approved Country/TerritoryN/A
Original Approved Date1989/01/01
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesClinigen Inc
China Registration ClassN/A

Develop Information

Active CompaniesClinigen Healthcare LtdClinigen IncJiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd
Inactive CompaniesJohns Hopkins Bloomberg School Of Public HealthAstra (U.S.A.) IncNational Institute Of Allergy And Infectious Diseases (Niaid)
Active IndicationsHerpes SimplexHerpesviridae InfectionsCytomegalovirus Retinitis
Inactive IndicationsGastrointestinal DiseasesAcquired Immunodeficiency SyndromeHIV Infections

Other Information

ATC CodeJ05AD01
Related LinksWikipediaDrugBankKEGG